UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 9, 2021

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

On March 9, 2021, Microbot Medical Inc. (the "Company") posted updated presentation materials on its website.

The presentation materials can be accessed via the 'Investors' section, under 'Presentation + Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The presentation materials furnished as Exhibit 99.1 to this Current Report on Form 8-K are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Presentation Materials

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: March 9, 2021

Exhibit 99.1

microbot medical

SAFE HARBOR STATEMENT

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, INC. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: risks inherent in the development and/or commercialization of potential products, including LIBERTY and the self-cleaning shunt; the outcome of our studies to evaluate LIBERTY and the SCS and other existing and future technologies; uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals; uncertainty resulting from the COVID-19 pandemic; need and ability to obtain future capital; maintenance of intellectual property rights; our ability to find and develop applications for our technologies for other neurosurgical conditions besides hydrocephalus; our clinical development and other research and development plans and expectations; the safety and efficacy of our product candidates; the anticipated regulatory pathways for our product candidates; our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING

SURGICAL ROBOTICS GROWTH OPPORTUNITY

U.S. Market for Surgical Robotics

Microbot Medical is in the Right Market, at the Right Time with the Right Products!

HEALTHCARE LANDSCAPE
POSITIONED FOR POST COVID-19

- Telehealth has been a core focus of Microbot's product development roadmap
- LIBERTY and SCS are designed to be remote controlled and monitored

Cardiovascular Today, April 2020
COVID-19: Robotics may help to reduce exposure to virus patients during interventional procedures

ResearchGate, March 2020
Robotics For COVID-19: How Can Robots Help Health Care in the Fight Against Coronavirus?

WIRED, March 2020
The Covid-19 Pandemic Is a Crisis That Robots Were Built For

MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT

Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Assisted Surgery Strategy.
Globe Newswire, February 2020

Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount.
Globe Newswire, February 2020

Stryker Acquires Mobius Imaging and Cardan Robotics for $370 million upfront and up to $130 million of contingent payments correlated with development and commercial milestones.
Globe Newswire, September 2019

Corindus Vascular Robotics Announces Definitive Agreement to be Acquired by Siemens Healthineer for $1.1 billion
Business Wire, August, 2019

Johnson & Johnson Acquires Auris Health, Inc for $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones.
Globe Newswire, April 2019

Medtronic Acquires Mazor Robotics for $1.64 Billion.
PR Newswire, September 2018

EVOLUTION OF SURGERY




Arterial
CNS
Digestive
Lymphatic
Musculatal
Respiratory
Urinary
Venous

BUILDING ON A SUCCESSFUL TRACK RECORD…

Strong Balance Sheet

LIBERTY Robotic System Validated Through Multiple Feasibility Studies

Successful Pre-submission Meeting with the FDA Regarding the SCS

Robust IP Portfolio:
41 Global Patents Issued/Allowed
24 Pending Patent Applications

Thought Leaders to Enhance Core Capabilities
- Expanded Management
- Scientific Advisory Board (Moshe Shoham)
- Board of Directors (Tal Wenderow)

…CONTINUED MOMENTUM IN 2021




liberty
microbot medical

FULLY DISPOSABLE ROBOTIC SYSTEM

Eliminate Need for Capital Equipment

Operated Remotely

"One & Done" Capabilities

TOTAL ADDRESSABLE MARKET - VASCULAR

~800K Stroke Incidences, US
Only ~4% Treated

Neuro

3+ M procedures WW

Coronary

2+ M procedures WW

Peripheral



ANIMAL FEASIBILITY STUDIES

First Study End Points Met

- Peripheral and Neuro Procedures Successfully Achieved
- No Intraoperative Adverse Effects
- Exceed internal expectations
- Confirmed Usability of the System with Leading KOL's

*The LIBERTY Robotic System is under its R&D phase, was not tested clinically and is not cleared for market within or outside the US


microbot
medical
liberty
microbot medical
* The Liberty Robotic System is under its R&D phase, was not tested clinically and is not cleared for market within or outside the US.

ANIMAL FEASIBILITY STUDIES

Second Study End Point Met

- Navigated to a clot
- Crossed the clot
- Deployed a stent retriever
- Retrieved an arterial clot in a live pig (manually)

liberty microbot medical

*All of the end points were met with no intraoperative adverse events.

CROSSING THE CLOT



INSERTION OF STENT RETRIEVER


MRT - 10513, MRT - 10513
10513
Standard
190.3 mGy
2326.23 µGy*m²
00:14:45 hh:mm:ss
18.2 mGy/min
Road
Fluoro
Ready


MRT - 10513, MRT - 10513
10513
Standard
190.3 mGy
2326.23 µGy*m²
00:14:45 hh:mm:ss
18.2 mGy/min
Road
Fluoro
Ready

LIBERTY:
CLINICAL AND REGULATORY UPCOMING MILESTONES



microbot medical

SELF-CLEANING SHUNT (SCS): VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY

- Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain.
- Over 1,000,000 people in the United States currently live with hydrocephalus[1]



- The problem is often misdiagnosed as Dementia, Alzheimer's, or Parkinson's[2]
- NPH can cause dementia, difficulty in walking and urinary incontinence[2]

1. NIH, National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm
2. National Hydrocephalus Foundation. http://nhfonline.org/facts-about-hydrocephalus.htm

SUCCESSFUL FDA PRE-SUBMISSION MEETING FOR NOVEL SCS TECHNOLOGY

Affirmed Steps to Advance through the Next Developmental, Clinical & Regulatory Phases



ROBUST IP PLATFORM

- Tip-Propelled Endoscope
- Restenosis Prevention
- Semi-disposable Endoscope
- Self-Cleaning Shut
- Multi-view Imaging System
- Robotic Crawler
- Double Concentric Guidewire
- Disposable Endoluminal Robotic System

PROVEN FOUNDERS

Prof. Moshe Shoham
Member of the Scientific Advisory Board

Prof. Moshe Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 25 years, with a special focus on kinematics and dynamics of robots, sensor integration, multi-finger hands and medical applications.

- Founder of Mazor Robotics Ltd. acquired by Medtronic for $1.64B
- International Member, US National Academy of Engineering
- Head of the robotics lab at Technion's - Israel Institute of Technology - Faculty of Mechanical Engineering. Formerly the director of the robotic laboratory of the Department of Mechanical Engineering, Columbia University, NY.

Harel Gadot
CEO, President & Chairman

Mr. Harel Gadot was formerly a Worldwide Group Marketing Director at Ethicon Inc., a multi-billion dollar division of Johnson & Johnson company (NYSE: JNJ). Mr. Gadot was with J&J for a decade between 2000- 2010.

- Company Group Chairman for MEDX Ventures Group.
- Previously held leadership positions for Ethicon Inc. in Europe, Middle East and Africa.
- Served on the board of directors and led the business development for ConTIPI Ltd., an early stage medical device company, which was acquired by Kimberly Clark Corp (NYSE:KMB) in 2012.

Yossi Bornstein
Co-Founder & Director

Mr. Yossi Bornstein is the President of Shizim Group, one of the leading MedTech eco-systems in Israel. He is a serial entrepreneur who played key roles in the healthcare industry over the past 35 years and is recognized for his activity both in Israel and internationally.

- He is a founder of multiple successful HealthCare companies and innovation centers, among them ShizimXL and ShizimVS.
- Founder of ILSI-Israel Life Science Industry Organization and ITTN-Israel Tech Transfer Organization
- Previously he held the position of CEO at Bristol-Myers Squibb (BMS) in Israel.

PROVEN LEADERSHIP TEAM

Simon Sharon
Chief Technology Officer

Mr. Simon Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical; an early stage, public medical device company. Mr. Sharon was the General Manager of Anorad Israel, a subsidiary of Rockwell Automation which manufactures sub-micron precision motion systems.

- Holds a B.Sc. from the Technion Institute of Technology and an M.Sc in Mechanical engineering from MIT where he specialized in motion control and Robotics.

Dr. Eyal Morag
Chief Medical Officer

Dr. Eyal Morag will lead the development and execution of the clinical strategy of the Company's technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline.

- Member of the Company's Scientific Advisory Board since November 2017.
- Serves as Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel.
- Recently served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio.
- Member of University Radiology Group (one of the largest private Radiology groups in the U.S.) where he headed the International Investment efforts for the Ventures division.

David Ben Naim
Chief Financial Officer

Mr. David Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial.

- Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:INSL).
- Prior to that Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, a public company listed on the OTCQB (CRWTF), from 2008 – 2011.

SUMMARY

- Addressing multi-billion, high growth, underserved markets
- Developing micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs
- Multi-generational product pipeline portfolio with robust launch cadence
- Significant Intellectual Property portfolio creates barrier to entry
- Proven leadership team and continued involvement of founders, including Prof. Moshe Shoham, founder of Mazor Robotics
- Strong cash position to achieve meaningful milestones